Advertisement

Chemotherapy pp 105-111 | Cite as

Adriamycin Metabolism in Man

  • Nicholas R. Bachur

Abstract

Over the past eight years, adriamycin, the outstanding representative of the anthracycline antibiotics, has demonstrated a remarkable activity against human and animal malignancies (1,2). Whereas adriamycin’s sibling, daunorubicin, has been impressive for remission induction in acute myelogenous and acute lymphocytic leukemias, adriamycin has a wider spectrum of activity and is useful against solid tumors. Clinical investigators in Europe, the Americas, Asia, and Africa find adriamycin has anticancer activity against soft tissue sarcomas, breast cancer, lung cancer, hepatomas, lymphomas, acute leukemias, etc. Against some malignancies, adriamycin has no useful pharmacologic activity. Complicating the usage of both adriamycin and daunorubicin are the toxic effects: myelosuppression, stomatitis, nausea, vomiting, alopecia, electrocardiographic changes, and a serious cumulative dosage related myocardiopathy.

Keywords

Acute Lymphocytic Leukemia Soft Tissue Sarcoma Acute Leukemia Amino Sugar Human Bile 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    International Symposium on Adriamycin. Ed. S.K. Carter, A. DiMarco, M. Ghione, I.H. Krakoff, and G.. Mathe, Milan 1971, Springer-Verlag, Berlin, 1972.Google Scholar
  2. 2.
    Adriamycin New Drug Symposium. Ed. N.R. Bachur, R.S, Benjamin, and T.C. Hall, San Francisco 1975, Cancer Chemother. Rep., in press.Google Scholar
  3. 3.
    Pigram, W.J., Fuller, W., and Hamilton, L.D.: Nature, New Biol. 235, 17 (1972).CrossRefGoogle Scholar
  4. 4.
    Waring, M: Progress in Molecular and Subcellular Biology. Ed. F.E. Hahn, Springer-Verlag, Berlin 2, 216 (1971).Google Scholar
  5. 5.
    Axelrod, M., Kaber, M., Bachur, N.R,: Unpublished observationsGoogle Scholar
  6. 6.
    Meriwether, W.D. and Bachur, N.R.; Cancer Res. 32, 1137 (1972).PubMedGoogle Scholar
  7. 7.
    Bachur, N.R., Hildebrand, R.C., and Jaenke, R.S.: J. Pharmacol. Exp. Ther. 191, 331 (1974).PubMedGoogle Scholar
  8. 8.
    Whang Peng, J., Leventhan, B.G., Adamson, J.W., and Perry, S.: Cancer 23, 113 (1969).PubMedCrossRefGoogle Scholar
  9. 9.
    Egorin, M.J., Hildebrand., R.C., Cimino, E.F., and Bachur, N.R.: Cancer Res. 34, 2243 (1974).PubMedGoogle Scholar
  10. 10.
    Felsted, R.L., Gee, M., and Bachur, N.R.: J. Biol. Chem. 249, 3672 (1974).PubMedGoogle Scholar
  11. 11.
    Bachur, N.R., Takanashi, S., Arena, E.: Proc. XI Inter. Cancer Congress, Florence (1974).Google Scholar
  12. 12.
    Bachur, N.R. and Gee, M.: J. Pharmacol. Exp. Ther. 177, 567 (1971).PubMedGoogle Scholar
  13. 13.
    Bachur, N.R. and Gee, M.: Fed. Proc. 31, 835 (1971).Google Scholar
  14. 14.
    Takanashi, S. and Bachur, N.R.: Proc. Amer. Assoc. Cancer Res. 15, 76 (1974).Google Scholar
  15. 15.
    Benjamin, R.S., Riggs, C.E., Jr., Serpick, A.A., and Bachur, N.R.: Clin. Res. 22, 483 (1974).Google Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • Nicholas R. Bachur
    • 1
  1. 1.Baltimore Cancer Research CenterNCIBaltimoreUSA

Personalised recommendations